Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy

Clin Adv Hematol Oncol. 2019 Jul;17(7):382-385.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Abiraterone Acetate / administration & dosage*
  • Absorptiometry, Photon
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Benzamides
  • Bone Neoplasms* / blood
  • Bone Neoplasms* / diagnostic imaging
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / secondary
  • Docetaxel / administration & dosage
  • Humans
  • Male
  • Neoplasm Metastasis
  • Nitriles
  • Phenylthiohydantoin / administration & dosage
  • Phenylthiohydantoin / analogs & derivatives
  • Prednisolone / administration & dosage*
  • Prednisone / administration & dosage
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / drug therapy
  • Zoledronic Acid / administration & dosage*

Substances

  • Benzamides
  • Nitriles
  • Docetaxel
  • Phenylthiohydantoin
  • Zoledronic Acid
  • enzalutamide
  • Prednisolone
  • Prostate-Specific Antigen
  • Abiraterone Acetate
  • Prednisone